Immunotherapy of Renal Cell Carcinoma pp 75-81 | Cite as
Recombinant Interferon Alpha Plus Vinblastine in Metastatic Renal Cell Cancer: Updated Results
Abstract
Recombinant interferon alpha (IFNα) has been shown to be effective in the treatment of metastatic renal cell cancer (RCC) with response rates in the order of 5%–15% [1–4]. In the hope of improving these results, in 1984 we started a phase I–II study of the combination of IFNα-2a with vinblastine in advanced RCC. Twenty-one patients were entered in this study, in which a dose escalation program permitted us to define the maximal tolerated doses of both drugs in this population. The combination was effective at tolerable doses, and the response rate (39% complete and partial remission, CR + PR) was very encouraging [5]. Based on the results of this first study, we have been conducting since 1985 a phase n study combining fixed doses of IFNα-2a and vinblastine, the preliminary results of which have been published elsewhere [6]. In the present paper we wish to update our experience with this combined therapy in 71 patients with metastatic RCC and to present some information on the prognostic factors, the duration of remission, and the impact on survival.
Keywords
Renal Cell Cancer Metastatic Renal Cell Carcinoma Recombinant Interferon Nonresponding Patient Metastatic Renal Cell CancerPreview
Unable to display preview. Download preview PDF.
References
- 1.Kempf RA, Grimberg SM, Daniels JR etal. (1983) Recombinant interferon alpha 2 in a phase II study of renal cell carcinoma. Proc Am Soc Clin Oncol 3: 59Google Scholar
- 2.Krown SE, Eizing AI, Abrahamson JD, Oettgen HF (1983) Treatment of advanced renal cell cancer with recombinant leucocyte A interferon. Proc Am Soc Clin Oncol 2: 58Google Scholar
- 3.Neidhardt JA (1986) Interferon therapy for the treatment of renal cancer. Cancer 57: 1696–1699CrossRefGoogle Scholar
- 4.Quesada JE, Swanson DA, Trindale A, Guttermann JV (1983) Renal cell carcinoma: Antitumor effects of leucocyte interferon. Cancer Res 43: 940–943PubMedGoogle Scholar
- 5.Bergerat JP, Dufour P, Soyer Y etal. (1987) Traitement des adenocarcinomas rénaux métastatiques par l’association interferon recombinant alpha-2a et vinblastine. Presse Med 16: 1953–1956PubMedGoogle Scholar
- 6.Bergerat JP, Herbrecht R, Dufour P etal. (1988) Combination of recombinant interferon alpha 2a and vinblastine in advanced renal cell cancer. Cancer 62: 2320–2324PubMedCrossRefGoogle Scholar
- 7.Fossa SD, Cavalli F, Otto U etal. (1988) Randomized study of Roferon-A with or without vinblastine in advanced or metastatic renal cell cancer. Proc Am Soc Clin Oncol 7: 118Google Scholar
- 8.Fossa SD, de Garis ST, Heier MS etal. (1986) Recombinant interferon alpha-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 57: 1700–1704PubMedCrossRefGoogle Scholar
- 9.Schornagel J, Verwey J, ten Bokkel Huinink W etal. (1987) Phase II study of recombinant interferon alpha-2 (IFN) and vinblastine (V) in advanced renal carcinoma (ARC). Proc Am Soc Clin Oncol 6: 106Google Scholar
- 10.Neidhart J, Harris J, Tuttle R (1987) A randomized study of wellferon (WFN) with or without vinblastine (VLB) in advanced renal cancer. Proc Am Soc Clin Oncol 6: 239Google Scholar
- 11.Figlin RA, de Kernion JB, Maldazys J, Sarna G (1985) Treatment of renal cell carcinoma with alfa (human leucocyte) interferon and vinblastine combination: A phase I-n trial. Cancer Treat Rep 69: 263–267Google Scholar
- 12.Kirkwood JM, Harris JE, Very R etal. (1985) Randomized study of low and high doses of leucocyte alfa-interferon in metastatic renal cell carcinoma. Am Cancer Soc Collaborative Trial Cancer Res 45: 863–871Google Scholar
- 13.Quesada JR, Guttermann JV, Rios A (1983) Investigational therapy of renal cell carcinoma with recombinant alfa-interferon. Prof Am Assoc Cancer Res 24, 195Google Scholar
- 14.Vugrin D, Hood L, Lazio J (1985) A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma. Cancer Treat Rep 69: 817PubMedGoogle Scholar